NeuroDerm Ltd. Ordinary Shares
NDRM
NDRM was delisted on the 17th of October, 2017.
81 hedge funds and large institutions have $501M invested in NeuroDerm Ltd. Ordinary Shares in 2017 Q3 according to their latest regulatory filings, with 46 funds opening new positions, 18 increasing their positions, 13 reducing their positions, and 38 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
38% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 13
21% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 38
20% more capital invested
Capital invested by funds: $418M → $501M (+$83M)
11% more funds holding
Funds holding: 73 → 81 (+8)
3% less call options, than puts
Call options by funds: $2.75M | Put options by funds: $2.83M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AA
AQR Arbitrage
Greenwich,
Connecticut
|
+$50.4M |
| 2 |
SAM
Sandell Asset Management
New York
|
+$41.5M |
| 3 |
OP
Omni Partners
London,
United Kingdom
|
+$41.1M |
| 4 |
JP Morgan Chase
New York
|
+$27.2M |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$21.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Scopia Capital Management
New York
|
-$154M |
| 2 |
MMH
Menora Mivtachim Holdings
Ramat Gan,
Israel
|
-$24.2M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$23.2M |
| 4 |
Viking Global Investors
Stamford,
Connecticut
|
-$21.2M |
| 5 |
Franklin Resources
San Mateo,
California
|
-$19M |
NDRM Hedge Fund Activity: Q3 2017 in Review
81 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in NeuroDerm Ltd. Ordinary Shares (NDRM) for Q3 2017, worth a combined $501M — up 20% from $418M a quarter earlier.
Buyers outnumbered sellers: 46 funds opened new NDRM positions and 38 closed out — a net gain of 8 holders — while 18 added to existing stakes and 13 trimmed.
The largest buyer was AQR Arbitrage, opening a new position worth an estimated $50.4M. The largest seller was Scopia Capital Management, cutting an estimated $154M.
- 81 institutional investors held NeuroDerm Ltd. Ordinary Shares (NDRM) as of Q3 2017, up from 73 in Q2 2017.
- Funds reported $501M of NeuroDerm Ltd. Ordinary Shares stock for Q3 2017, up 20% quarter-over-quarter.
- 46 funds opened new NeuroDerm Ltd. Ordinary Shares positions in Q3 2017 and 38 closed out, a net change of +8 holders.
- The largest NeuroDerm Ltd. Ordinary Shares buyer in Q3 2017 was AQR Arbitrage, an estimated $50.4M added.
- The largest NeuroDerm Ltd. Ordinary Shares seller in Q3 2017 was Scopia Capital Management, an estimated $154M sold.
Based on aggregated 13F filings for Q3 2017.